GlassScriptPhysician profile
Steven Frederick Scheibel
NPI 1649410069
$1,373.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $591.60 | 2019 | |
| Gilead Sciences, INC. | $215.83 | 2019 | |
| Janssen Biotech, INC. | $163.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $94.40 | 2019 | |
| Merck Sharp & Dohme LLC | $79.84 | 2019 | |
| Janssen Products, LP | $72.00 | 2019 | |
| Emd Serono, INC. | $51.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.90 | 2019 | |
| Theratechnologies INC. | $20.19 | 2019 | |
| Shionogi INC | $19.34 | 2019 | |
| Amarin Pharma, INC. | $16.41 | 2019 | |
| Allergan, INC. | $13.70 | 2019 | |
| Antares Pharma, INC. | $12.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Scheibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.